HCM
SRPT icon

Highline Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Highline Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-436,000
Closed -$52M – 41
2019
Q1 		$52M Buy
436,000
+311,723
+251% +$40.1M 3.27% 14
2018
Q4 		$13.6M Buy
+124,277
New +$15.5M 0.91% 26

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Highline Capital Management's SRPT Position: Q2 2019 in Review

Highline Capital Management sold out of Sarepta Therapeutics (SRPT) in Q2 2019, closing a stake of 436,000 shares — an estimated $52M sold.

Highline Capital Management first reported a position in SRPT in Q4 2018 and held it in 2 quarters. The position peaked at $52M in Q1 2019. 365 funds tracked by Wall St. Rank hold SRPT as of Q2 2019.

  • Highline Capital Management reported no remaining Sarepta Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Highline Capital Management sold 436,000 Sarepta Therapeutics shares in Q2 2019, an estimated $52M.
  • Highline Capital Management first reported a position in Sarepta Therapeutics in Q4 2018 and held it in 2 quarters.
  • Highline Capital Management's Sarepta Therapeutics position peaked at $52M in Q1 2019.
  • 365 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2019.

Based on Highline Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.